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Abstract
Background: Epidemic P. aeruginosa (ePA) infections are common in cystic fibrosis (CF) and have been associated
with accelerated clinical decline. Factors associated with ePA are unclear, and evidence based infection control
interventions are lacking.
Methods: We prospectively collect all bacterial pathogens from adult CF patients. We performed PA strain typing
on retrospectively collected enrolment samples and recent isolates to identify patients infected with ePA. All
patients attending our clinic were approached to complete a survey on infection control knowledge, beliefs and
exposures. We analyzed responses of those with ePA relative to the entire cohort without ePA as well as those
infected with unique strains of P. aeruginosa to assess for risk factors for ePA and differences in infection control
knowledge, beliefs or behaviours.
Results: Of 144 participants, 30 patients had ePA (two Liverpool epidemic strain, 28 Prairie epidemic strain), 83 %
of which had established infection prior to transition to the adult clinic. Risk of concomitant infecting pathogens
was no different between groups although, Staphylococcus aureus and non-tuberculous mycobacteria were less
common in those with ePA. Patients with ePA were more likely to have attended CF-camp and have a history of
CF fundraising. Patients with ePA did not differ with respect to beliefs regarding pathogens or transmission risk,
except they believed indirect contact posed little risk. Furthermore, patients with ePA were more likely to
continue to associate with others with CF despite extensive counselling. Use of peer-peer online networking was
minimal in both groups.
Conclusion: Infections with ePA are closely linked to past exposures, now routinely discouraged. As socialization
is the greatest risk factor for ePA, infection control strategies for ePA must focus on discouraging face-to-face
interactions amongst CF patients. As peer support remains a desire amongst patients, investment in technologies
and strategies that enable indirect communication and support are required.
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Background
Cheng et al. are largely recognized as identifying the first
epidemic P. aeruginosa (ePA) infecting individuals with CF
[1]. These researchers identified disproportionally high rates
of ceftazidime resistance amongst P. aeruginosa isolated
from their pediatric population and subsequently geno-
typed all isolates using molecular methodology identifying
85 % of patients harbored the same strain, the Liverpool
Epidemic Strain (LES). LES has since been identified to be
widespread in clinics across the United Kingdom, and in
Eastern Canada [2–5]. Furthermore, multiple other ePA
strains have since been described in Australia, Europe and
North America [2, 3, 6–9].
Patients chronically infected with many of the ePA strains
are associated with a worsened clinical course relative to
those infected with unique, non-clonal strains. In particular,
LES has been associated with increased rates of lung func-
tion decline, exacerbation frequency and progression to
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end stage lung disease [2, 10, 11]. We have recently de-
scribed another ePA, termed the Prairie Epidemic Strain
(PES), amongst patients attending the Calgary Adult Cystic
Fibrosis Clinic. PES is unique to CF, and was not found
causing infection in comparator populations of adults with
non-CF bronchiectasis, or community-acquired bacteremia
nor during extensive sampling of natural environmental
reservoirs or the local hospital sampling [7, 12]. This strain
was evident at first encounter amongst multiple patients
transferring to our adult clinic from other Western Canad-
ian CF clinics suggesting PES is prevalent across the Prai-
ries [7]. PES was observed to exist in even the earliest
samples collected in 1980 (unpublished observations), and
has been identified in sequential cohorts of young adults
transitioning into our clinic. Most importantly, infection
with PES occurred almost universally prior to adulthood,
and very few cases of super-infection were documented in
an adult cohort despite prolonged follow-up [7]. Like LES,
PES has been associated with a worse baseline lung func-
tion and nutritional status, increased rates of lung function
decline and progression to end stage lung disease, and are
more likely to be resistant to antibiotics [7, 13].
Risk factors for ePA are poorly understood. One of the
major limitations is lack of historical context to determine
when infections have occurred as most ePA related studies
are prospective and of short duration. As we were previ-
ously able to establish infections occur generally prior to
adulthood we sought to determine what behaviours and
exposures associated with ePA infection. Few studies have
been conducted on patient beliefs and behaviours with re-
spect to infection control [14]. To date no published
works have sought to determine if patients with transmis-
sible pathogens in CF have different behaviours and beliefs
that may explain their infection status and contribute to
risk for spread. Accordingly we sought to prospectively as-
sess attitudes, behaviours and beliefs amongst our clinic
cohort regarding infection control to identify potential
factors that may lead to lapses in infection control.
Methods
Patient population
The Adult Cystic Fibrosis Clinic at the Foothills Medical
Center, established in 1978, follows and provides all pri-
mary and specialty CF care to those with CF residing in
Southern Alberta, Canada. Upon enrolment in our clinic,
all patients provide prospective consent for the collection,
storage and study of sputum and sputum-derived organ-
isms (CHREB E-23087). This established prospectively
collected biobank includes all morphologically distinct
bacterial isolates from each and every encounter dating
back to 1978. Accordingly we have been able to identify
infecting pathogens and perform genotyping on P. aerugi-
nosa upon enrolment in the clinic and from the most re-
cently available clinical samples [7].
Infection control strategy
Prior to 2010 the focus on infection control in the clinic
merely involved vigorous adherence to hand and cough
hygiene, as well as maintaining a 1 m “protective bubble”
between patients. In 2010, these principles were expanded
to include mandatory segregation of all patients to private
exam rooms (including spirometry) with no possibility for
co-mingling, an expansion of the “protective bubble” to
2 m in size, and contact isolation for individuals who had
cultured any methicillin resistant Staphylococcus aureus
(MRSA) in the prior 2 years. We perform bacterial strain
typing by pulse-field gel electrophoresis (PFGE), supple-
mented with multi-locus sequence typing (MLST) and/or
whole genome sequencing (WGS) for any suspected
transmission of P. aeruginosa or other respiratory patho-
gens but have not observed any transmission events dur-
ing five years of surveillance [15].
Definitions
Chronic infection with P. aeruginosa was defined as per
the Leeds criteria [16]. Infection with another airways
pathogen was defined as at least one positive culture in
the year prior to assessment, although patients on chron-
ically suppressive M. abscessus therapy that no longer
grew this organism were considered positive for the length
of their treatment.
Strain typing
Bacterial strain typing was performed using pulsed-field
gel electrophoresis following protocols established by our
group [7]. For each time point all morphotypes of P. aeru-
ginosa (defined as morphologically distinct populations on
MacConkey agar) were assessed. For those patients who
were recipients of life saving bilateral lung transplantation,
we used sputum culture samples collected immediately
prior to their transplant to define their airway infection
status (as other groups have established concordance be-
tween pre- and post transplant infecting P. aeruginosa
which continue to infect the sinuses and periodically the
graft) [17]. Strains deemed potentially ePA were those that
existed in greater than three individuals from different
kindreds, or previously recognized ePA strains. In situa-
tions where PFGE determination was questioned, MLST/
WGS was used to confirm results.
Survey
All patients attending the clinic were approached to
complete a survey pertaining to infection control. In par-
ticular, past behaviours and risks for acquisition of infec-
tion were queried targeting childhood and early adulthood
exposure as establishment of ePA infection have been
demonstrated to have occurred earlier than age 20 within
this cohort [7]. We sought to establish current knowledge
and beliefs regarding infection control with respect to:
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individual pathogens; situations, and interventions in those
with ePA relative to those with UNI (chronic stable unique
P. aeruginosa) and ENT (the entire cohort who did not
have ePA). This survey was completed using a 7-point
Likert scale where the following values were used: 1. No
risk, 2. Very low risk, 3. Low risk, 4. Neutral, 5. Mild risk,
6. Moderate risk, 7. Extreme risk [18, 19]. Finally, current
behaviours and preferences were assessed using a 7-point
Likert scale; 1. Strongly disagree, 2. Disagree, 3. Neutral, 4.
Neither agree or disagree, 5. Somewhat agree, 6. Agree, 7.
Strongly Agree. A complete reference to the survey is avail-
able in the appended supplemental material section. While
patients were aware of their own lower airways pathogens
in principle, they were not aware of whether their particu-
lar P. aeruginosa strains were ePA as typing occurred con-
current to the survey. Informed written consent was
obtained from each participant. Ethical approval of this
study was granted by the Conjoint Health Region Ethics
Board (E-24123).
Statistics
Statistical analysis was performed using Stata version 11.0
(Stata- Corp, TX, USA). Asymmetrically distributed vari-
ables were reported as medians with interquartile range
(IQR) and compared using the Wilcoxon rank-sum test
for pairs or the Kruskal-Wallis test for multiples. Differ-
ences in proportions among categorical data were assessed
using Fisher’s exact test for pair-wise comparisons and the
Chi-square test for multiple groups and reported as odds
ratio (OR) with confidence intervals (CI). Significance was
based on α < 0.05, and all hypothesis tests were 2-sided.
Results
Patient demographics
One hundred and forty-four of 169 active patients (85 %)
within the clinic cohort participated in the study. Demo-
graphic and infection factors were not different between
participants and those few non-participants. Median age
of the cohort was 30.2 years (IQR 24.9–40.2) and 79
(55 %) were female. 25 patients (17.3 %) were recipients of
saving lung transplantation. Sixty-nine percent of the co-
hort (99/144) had chronic P. aeruginosa infection as de-
fined by the Leeds criteria. All but two patients with
chronic P. aeruginosa underwent bacterial strain typing
(98 %). Those two patients were unable to be categorized
for the following reasons; one did not produce sputum
(PA status determined by cough swab – but these isolates
are not available for typing) and one patient transferred to
our clinic following transplant and thusly pre-transplant
samples were unavailable for assessment. Twenty–one
percent (30/142) individuals in the cohort were chronic-
ally infected with ePA and 48 % (68/142) were infected
with UNI. Of the ePA, 28 patients were infected with PES
and two with LES. Patient demographic factors did not
significantly differ amongst those with ePA infection
relative to those with UNI or ENT (Table 1) with the
exception of pancreatic insufficiency ePA 29/30 (97 %)
vs non-ePA [93/112 (83 %), RR 1.16, CI 1.04–1.29. Pa-
tients with ePA were no more likely to have concurrent
infection with other pathogens (Table 1). In fact, patients
with ePA were less likely to have concurrent chronic S.
aureus infection or non-tuberculous mycobacteria (NTM).
Of patients with ePA, 25/30 acquired infection prior to
transition to the adult CF clinic. In those five with ePA
super-infections as an adult, these infections were ac-
quired within the first 2 years of transfer and none oc-
curred in the last decade outside of one siblingship where
the older of the pair had established infection prior to
transfer to the adult clinic (data not shown) [7]. We also
assessed how many prior CF clinics patients had attended
as infection risk may be clinic dependent. 10 (7 %) had
attended only our adult CF clinic, 73 (51.7 %) had
attended two clinics (generally the local pediatric CF clinic
and the local adult clinic), 38 (26.9 %) had attended three,
13 had attended four (9 %) and seven had attended five or
more clinics (5 %). There was no association with num-
ber of clinics attended and risk of ePA clinic 0/10 (0 %),
two clinics 16/73 (21.9 %), and ≥3 clinics 14/58
(24.1 %), p = 0.30.
Risk for acquisition of ePA
Risk factors were assessed for ePA by asking patients
about exposures occurring in their childhood or early
adulthood. Most notably, patients with ePA were more
likely to have attended summer camps (Table 2). Fur-
thermore, patients with ePA were more likely to have
directly participated in CF fundraising activities which
had social components associated with them although
this did not extend to individuals with family members
partaking in CF fundraising activities. Having a family
member with CF did not increase risk of ePA infection.
Knowledge regarding infection transmission potential
Patients with ePA did not significantly differ from those
without regarding beliefs around risks and mechanisms
of pathogen transmission (Table 3). Both groups recog-
nized the risk of infection acquisition from aerosol, fo-
mite and through health care workers (Table 3). In both
groups patients demonstrated an understanding of patho-
gens with potential transmission potential and demon-
strated a heightened concern regarding organisms such as
Burkholderia cenocepacia, P. aeruginosa, and methicillin
resistant S. aureus (MRSA) relative to other organisms
such as S. maltophilia, and Aspergillus spp, and were not
different amongst those infected with ePA (data not
shown). Patients with ePA were more knowledgeable and
concerned with respect to B. cenocepacia (Table 4). Both
groups recognized that patients who have undergone
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transplantation were at increased risk of acquiring in-
fections but participants were ambivalent as to whether
those who had received transplant posed a risk for
propagating infection.
Whereas patients recognized the risk of infection trans-
mission with failure to comply with mandatory hand hy-
giene on the part of staff and patients alike, both groups
were less concerned about acquisition from the clinic en-
vironment (Table 4). Most notably, patients from both
groups believed that infection acquisition was much more
likely to occur during exposure to a CF patient coughing
as opposed to merely talking. Furthermore, neither group
was particularly concerned about the role of spirometry in
aerosol generation.
We assessed several factors related to patient preference
and attitudes. Patients were generally against grouping of
individuals in common waiting rooms (ePA 3 (IQR 2–5)
vs ENT 3.0 (IQR 1–4), p = 0.69), and preferred segregation
in private rooms through their entire clinic visit. Patients
generally suggested they were not concerned with acquir-
ing infection in clinic; ePA 5 (IQR 2–6) vs ENT 5 (IQR 2–
6), p = 0.93 and did not cite fear of infection as a reason
for not attending clinic; ePA 1 (IQR 1–2) vs ENT 1 (IQR
1–2), p = 0.43. Few patients suggested they would prefer
to be seen outside of CF clinic altogether, ePA 2 (IQR 1–4)
vs ENT 2 (IQR 1–4), p = 0.64. However, socialization with
others with CF was seen more commonly in those with
ePA(Table 4). When asked if they would continue to
socialize outside of CF clinic together patients with ePA
were more likely to do so; ePA 5 (IQR 4–6) vs ENT 4 (IQR
2–5), p = 0.03 and UNI 4 (IQR2-6), p = 0.06. The same
trend was observed in patients response to interacting on
clinic days; ePA 5 (IQR 2–5) vs ENT 3(IQR 2–5), p = 0.05
and UNI 3 (IQR2-5), p = 0.08. Whereas past fundraising
activities were observed to associate with ePA, participants
did not agree that CF individuals should be excluded from
future events; ePA 2 (IQR 1–4) vs non 2 (IQR 1–4), p =
0.5. Patients were ambivalent towards, and many reported
being unaware of online social network platforms for those
with CF; ePA 4 (IQR 2–5) vs non 4 (IQR2-5), p = 0.93.
Discussion
ePA infection in CF, including infection with strains such
as LES and PES, have been associated with increased risk
of disease progression and worsened pre-transplant sur-
vival [2, 13]. Accordingly, strategies to prevent transmis-
sion of ePA are of paramount importance.
Table 1 Patient Demographics as a function of chronic infection with epidemic P. aeruginosa strains
Category Epidemic P.
aeruginosa (n = 30)
Cohort with unique chronic P. aeruginosa infection Entire CF cohort without epidemic
P. aeruginosa
UNI (n = 67) P Value ENT (n = 112) P Value
Age 32.81 (IQR 29.5–39.3) 29.61 (IQR 24.9–41.9) 0.13 29.5 (IQR 23.7–42.5) 0.10
Gender (Female) 17 (56.7 %) 40 (60 %) 0.48 60 (53.4 %) 0.84
Pancreatic Sufficient 1 (3.3 %) 6 (9 %) 0.3 19 (17 %) 0.07
F508 del Homozygous 18 (60 %) 37 (56 %) 0.44 56 (50 %) 0.42
≥1 F508del allele 27 (90 %) 57 (66 %) 0.5 93 (83 %) 0.56
Status post lung transplant 12 (40 %) 9 (13.4 %) 0.005 12 (10.7 %) <0.001
Age at transplant 29 (IQR 24.5–31.2) 33.27 (IQR 23.4–35.7) 0.53 33.9 (IQR 23.3–38.3) 0.41
Chronic Infection Status
P. aeruginosa 30 (100 %) 67 (100 %) N/A 67 (59.8 %) <0.001
S. aureus (MSSA) 5 (20 %) 29 (43.7) 0.009 61 (54.5 %) <0.001
MSSA as sole pathogen 0 0 N/A 21 (18.8 %) 0.007
S. aureus (MRSA) 1 (3 %) 3 (5 %) 0.63 8 (7 %) 0.68
S. maltophilia 0 0 N/A 2 (2 %) 1
Non-tuberculous mycobacteria 0 6 (9 %) 0.1 17 (15.1 %) 0.02
M. abscessus complexa 0 2 (3 %) 0.48 10 (9 %) 0.12
M. avium complex 0 4 (6 %) 0.22 7 (6 %) 0.34
A. xylosoxidans 0 0 N/A 2 (2 %) 1
B. cepacia complex (Bcc)b 1 (3 %) 2 (3 %) 0.67 4 (3.5 %) 1
Aspergillus fumigatus 2 (6.6 %) 2 (3 %) 0.36 5 (4.5 %) 0.64
No chronic pathogens 0 0 N/A 6 (5.3 %) 0.34
aM. abscessus complex = 8M. abscessus abscessus, 2M. abscessus bolletti
bBcc = B. multivorans 1, B. cenocepacia 3
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Risk factors for acquisition of ePA have often been dif-
ficult to ascertain owing to uncertainty regarding timing
of infection in prospective studies. As our group has
previously demonstrated that ePA acquisition occurs be-
fore or shortly after adulthood [7], we looked to identify
which past behaviours were most closely associated with
ePA. Herein, we identified the greatest risk factor for
ePA acquisition to be during periods of prolonged close
contact such as might occur during CF camps. Indeed
these camps were run through many parts of the world,
and several studies report instances of super-infection of
60–100 % of attendees [20, 21]. These camps were also
associated with outbreaks of Bcc and have largely since
been abandoned for this reason [22]. Whereas personal
involvement in past social CF fundraising was observed
to associated with ePA, current non-social fundraising
activities either by patients or family members was not
demonstrated to be a significant factor.
Others have reported significant gaps in infection control
knowledge of CF patients and family members [14, 23]. In
a multi-center survey involving 1399 patients, only 53 % of
patients understood the risks associated with socialization




Compared to those with
chronic unique P. aeruginosa
strains
Compared to the rest of the clinic
cohort irrespective of P. aeruginosa
status
UNI (n = 66) P Value ENT (n = 112) P value
Individuals with CF can spread germs to each other 6 (IQR 6–7) 7 (IQR 6–7) 0.54 7 (IQR 6–7) 0.87
B cepacia is a germ that can be spread 7 (IQR6-7) 6 (IQR 4–7) 0.04 6 (IQR 4–7) 0.03
Pseudomonas is a germ that can spread 6(6–7) 6 (6–7) 0.49 6 (6–7) 0.34
Staphylococcus is a germ that can spread 6 (6–7) 6 (5–7) 0.18 6 (5–7) 0.15
People with CF can spread infection via cough 7 (6–7) 6 (5–7) 0.14 6 (6–7) 0.2
Contaminated clinic surfaces such as chairs and desks can
spread infection
6 (6–7) 6 (5–7) 0.57 6 (5–7) 0.36
Healthcare workers can spread infection 6 (6–7) 6 (5–7) 0.52 6 (5–7) 0.4
Patients with lung transplants are at risk of acquiring infections 7 (6–7) 6 (5–7) 0.3 6 (6–7) 0.26
Patients with lung transplants are at risk of spreading infection 5 (4–6) 6 (4–7) 0.97 6 (4–7) 0.65
aStrongly Disagree, 2. Disagree, 3. Neutral, 4. Neither agree or disagree, 5. Somewhat agree, 6. Agree, 7. Strongly Agree
Table 2 Presence of prior exposures/risks associated with risk of epidemic P. aeruginosa chronic infection
Exposure Epidemic P. aeruginosa
(n = 30) (%)
Compared to those with chronic
unique P. aeruginosa strains
Compared to the rest of the clinic





ENT OR (CI) P Value
(n = 112)
(%)
Attended CF Camps 19/30 (63) 5/66 (8) 8.36 (3.45–20.3) <0.001 8/104 (8) 8.23 (4–16.9) p < 0.001
Personal Involvement in prior
fundraising events
16/30 (53) 18/66 (27) 1.96 (1.17–3.28) 0.02 30/103 (29) 1.83 (1.16–2.87) p = 0.02
Family member involved in CF
fundraising events
16/30 (53) 25/65 (38) 1.38 (0.88–2.19) 0.128 37/102 (36) 1.47 (0.96–2.24) p = 0.14
Have you ever lived with some
one with CF
9/30 (30) 21/65 (32) 0.93 (0.48–1.78) 1 26/102 (25) 1.17 (0.62–2.23) p = 0.64
Attended School or work with
someone with CF
6/30 (20) 19/66 (29) 0.70 (0.31–1.56) 0.46 20/103 (19) 1.03 (0.46–2.33) p = 1
Shared Medical Devices with
someone with CF
6/30 (20) 10/66 (15) 1.32 (0.53–3.30) 0.57 12/103 (12) 1.47 (0.96–2.24) p = 0.14
Shared Meals with someone
with CF (outside of Camps)
10/30 (33) 17/66 (26) 1.29 (0.67–2.48) 0.47 21/103 (20) 1.17 (0.62–2.23) p = 0.64
Intimate Contact with someone
with CFa
3/30 (10) 5/66 (8) 1.32 (0.34–5.17) 0.7 4/103 (4) 1.03 (0.46–2.33) p = 1
aDescribed as either kissing or a sexual relationship
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and social behaviours such as hand shaking (57 %) or the
rationale for the 1 m bubble (67 %) [24]. However, herein
we observed, in general our population to be quite
knowledgeable. We did, however, find that patients with
ePA were less likely to believe in or adhere to clinic policy
against socialization. Patients may believe that the benefit
of a close personal connection to other individuals with CF
outweigh the potential risk of infection transmission [14].
Others have reported that young adults are more likely to
be non-adherent to infection control standards than other
age groups, and this was postulated to be related to the
fact these patients grew up spanning two very different
periods of CF care. Indeed, these patients were also
more likely to have attended camps where socialization
was previously encouraged.
Droplet nuclei containing CF pathogens including P.
aeruginosa have long been known to be created by those
with CF [25, 26]. These have been shown to be the same
strains causing chronic infection and to persist in the air
for extended periods. However, in the absence of informa-
tion regarding minimum infectious inoculum for ePA the
risk of ePA in droplet nuclei within the clinic environment
is unknown. In our study, patients associated coughing
with heightened risk of infection acquisition but did not
equate mere talking as a risk. Indeed, many health care
works and patients believe that it is during periods of ill-
ness associated with increased coughing that the greatest
risk of transmission occurs [24]. This is not the case as
others have demonstrated that the amounts of infectious
droplets generated during cough were similar during
periods of stability and at exacerbation [27]. Indeed, P.
aeruginosa in droplet aerosol are even identified during
tidal breathing, albeit at lower levels then during cough.
While use of masks has been advocated in the recent
American infection control guidelines [28], recent work
suggests that masks do not reduce risk of infectious aero-
sol generation [29]. This raises the potential concern of
false security as use of masks may be viewed as a means
amongst CF patients to facilitate safer socialization.
Strategies adopted for controlling the spread of ePA are
quite diverse. Those advocated include: cohort segregation
(where patients infected with ePA are seen at separate
clinic/hospital facilities from those without) [30, 31], co-
hort segregation with environmental controls (whereby
patients with any P. aeruginosa infection were seen separ-
ately in addition to strict environmental controls including
faucet filters and splash back preventing sinks), and strict
patient segregation incorporating the use of gowns and
masks by patients and health care workers alike [32].
These increasingly complex strategies have all been attrib-
uted as being responsible for reduction in transmission.
However, based on our observations herein we put forth
that patient segregation, preventing socialization and the
basics of hand and cough hygiene are the primary means
of preventing ePA. Indeed, discussions about infection
control knowledge and beliefs, and critically avoiding
socialization with other unrelated CF individuals need to
be addressed, and become part of the annual review [33].
Whereas prevalence of ePA are discouragingly high
across multiple clinics, incident infections with these




Compared to those with
chronic unique P.
aeruginosa strains
Compared to the rest of the clinic
cohort irrespective of P.
aeruginosa status
Situations associated with risk of transmitting infections UNI (n = 66) P Value ENT (n = 112) OR, P value
Patients not washing hands 6 (6–7) 6 (5–7) 0.69 6 (6–7) 0.84
Health care workers not washing hands 7 (6–7) 7 (6–7) 0.91 7 (6–7) 0.87
Clinic environment between patients 5 (4–7) 6 (5–7) 0.07 6 (4.5–7) 0.13
Exposure to another CF patient coughing 6 (6–7) 7 (5–7) 0.66 7 (5–7) 0.87
Exposure to another CF patient talking 4 (2–4) 5 (2–6) 0.1 4 (2–6) 0.16
Spirometry performed in a PFT laboratory 6 (4–7) 6 (4–7) 0.98 4 (4–6) 0.63
Importance of various measures in reducing risk of infection transmission
Segregation of patients in to separate rooms 6 (5–7) 7 (5–7) 0.19 7 (6–7) 0.11
All patients washing hands/sterilizing with alcohol upon entry and
exit from rooms
7 (7–7) 7 (6–7) 0.11 7 (6–7) 0.10
Patients wearing a mask in hospital common areas 4 (3–6) 5 (3–7) 0.44 5 (3–6) 0.98
Cleaning of examination rooms between patients 7 (6–7) 7 (5–7) 0.59 7 (5–7) 0.41
Avoiding direct physical contact with other patients 6 (3–7) 6 (5–7) 0.49 6 (5–7) 0.49
Avoiding any contact with other CF individuals 3 (2–4) 5 (2–7) 0.05 5 (2–7) 0.04
aNo risk, 2. Very low risk, 3 low risk, 4 neutral, 5. Mild risk, 6. Moderate risk, 7. Extreme risk
direct = Any physical contact with an individual with CF
any = Any direct communication regardless of direct physical contact within the prescribed "2m" protective bubble
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strains remain very low when simple measures are in-
voked [2, 7]. In prospective studies, in the few instances
where ePA strains have been observed to superinfect pa-
tients, social connections have been identified [30, 34, 35].
Discouraging socialization thusly must be prioritized as ul-
timately the most important and controllable means of
preventing ePA transmission. However, studies have sug-
gested that CF care providers are often unfamiliar with the
importance of this strategy, or may disagree entirely, and
lack confidence in encouraging this practice [24, 36].
Within our cohort of patients we assessed if there was
an association between number of clinics attended and risk
of epidemic strains. While no association was found we
did observe a high frequency of patients attending multiple
CF clinics, including patients who had attended CF clinics
in all regions of Canada, parts of the United States, Europe
and Australia. As many surveillance projects rely exclu-
sively on screening against local epidemic strains, we must
remain mindful that focused strategies such as PCR target-
ing local epidemic strains may be insensitive to identifica-
tion of novel or new strains as new strains may become
established through patient transfers [30].
Interventions to improve infection control as it pertains
to ePA must account for the fact that social connectedness
appears to be the greatest risk factor. As this group seems
also to be the most inclined to socialize and thereby po-
tentially transmit infection, strategies both discouraging
face-to-face contact while supporting the desire and per-
ceived benefit of socialization need to be recognized. In
this light the use of CF “online” social networking sites
offer promise provided they can be adequately supported
and regulated. Indeed, “offline” face-to-face meetings do
occur and peer-to-peer or external safety measures must
be continually emphasized. Whereas online message
boards have traditionally been the means of communica-
tion, next generation peer-peer video chat and conference
call systems are being developed and hold greater promise
yet [37]. Unfortunately, uptake within the CF community
remains limited and both promotion and continued ex-
pansion of this medium to meet the evolving needs of the
community are required. Furthermore, social scientists
can monitor these medium enabling great insight into the
CF patient population with respect to beliefs, perception,
concerns and understanding how patients individualize
their disease and its management [38]. In an environment
where health care resources are increasingly limited,
and ever increasingly complex and expensive infection
control protocols exist we suggest that investment in
online platforms to enable these connections pose great
“bang for the buck”.
Conclusions
ePA infections are both common and associated with ac-
celerated clinical decline. The most important risk factor
for ePA infection remains peer-peer socialization, some-
thing now routinely discouraged. As patients continue to
desire peer-peer support, novel strategies that enable this
desire to be met are warranted. Investment in online peer-
peer communication technologies represents a cost effect-
ive intervention for preventing further ePA transmission.
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